BioTelemetry (BioTelemetry) Retained Earnings : $-70.3 Mil (As of Sep. 2020)

View and export this data going back to 2008. Start your Free Trial

What is BioTelemetry Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. BioTelemetry's retained earnings for the quarter that ended in Sep. 2020 was $-70.3 Mil.

BioTelemetry's quarterly retained earnings increased from Mar. 2020 ($-79.3 Mil) to Jun. 2020 ($-77.0 Mil) and increased from Jun. 2020 ($-77.0 Mil) to Sep. 2020 ($-70.3 Mil).

BioTelemetry's annual retained earnings increased from Dec. 2017 ($-158.7 Mil) to Dec. 2018 ($-115.9 Mil) and increased from Dec. 2018 ($-115.9 Mil) to Dec. 2019 ($-86.0 Mil).

BioTelemetry Retained Earnings Historical Data

The historical data trend for BioTelemetry's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioTelemetry Retained Earnings Chart

BioTelemetry Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Retained Earnings

Get a 7-Day Free Trial

-196.16

-142.72

-158.68

-115.86

-86.01

BioTelemetry Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Retained Earnings	Get a 7-Day Free Trial															-87.59	-86.01	-79.25	-76.97	-70.26

BioTelemetry Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

BioTelemetry (NAS:BEAT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

BioTelemetry (BioTelemetry) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioTelemetry Inc (NAS:BEAT) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Cedar Hollow Road, Suite 102, Malvern, PA, USA, 19355

Website

https://www.gobio.com

BioTelemetry Inc provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. It operates under healthcare, technology, and research segments. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials and the Technology segment, focuses on the development, manufacturing, testing, and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals.

Executives

Kirk E Gorman	director	367 SOUTH GULPH ROAD, KING PRUSSIA PA 19406
Stephen Rietiker	director	C/O BIOTELEMETRY, INC., 1000 CEDAR HOLLOW RD. SUITE 102, MALVERN PA 19355
Tiffany Olson	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Joseph A. Frick	director	ONE COMMERCE SQUARE 2005 MARKET ST., SUITE 3300 19103 PR 19073
Laura N. Dietch	director	1000 CEDAR HOLLOW RD. SUITE 102 MALVERN PA 19355
Anthony James Conti	director	76 GOLFVIEW DRIVE, IVYLAND PA 18974
Rebecca W Rimel	director	345 PARK AVENUE, NEW YORK NY 10154
Robert J. Rubin	director	7901 SPRINGER ROAD, BETHESDA MD 20817
Hill Colin	director	196 BROADWAY CAMBRIDGE MA 02139
Andrei G Stoica	officer: SVP & CTO	1000 CEDAR HOLLOW ROAD, MALVERN PA 19355
Joseph H Capper	director, officer: President & CEO	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Manish Wadhwa	officer: SVP & CMO	1000 CEDAR HOLLOW ROAD MALVERN PA 19355
Fred Broadway	officer: President BioTel Heart	BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Daniel Wisniewski	officer: SVP, Technical Operations	BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Heather C Getz	officer: EVP, CFO & CAO	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355